Inicio › Leucemia mielógena aguda › Massachusetts
Ensayos clínicos de Leucemia mielógena aguda en Massachusetts
46 estudios sobre Leucemia mielógena aguda buscan participantes en Massachusetts.
Ciudades en Massachusetts
Texto oficial del estudio (inglés)
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- Tufts Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
- Lahey Clinic, Burlington
- y 1 más
ReclutandoFase 2
Edades de 18 a 59 · Todos los sexos · Actualizado el 28 sept 2026 · NCT05554393Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes
- Dana-Farber Cancer Institute, Boston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 28 sept 2026 · NCT06484062A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
- Dana Farber Cancer Institute, Boston
- Beth Israel Deaconess Medical Center, Boston
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT06852222MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Tufts Medical Center, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
- y 1 más
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 sept 2026 · NCT05564390Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
- Tufts Medical Center, Boston
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT06672146Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- Tufts Medical Center, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
- y 2 más
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 22 sept 2026 · NCT06317649Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- Tufts Medical Center, Boston
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
- y 2 más
ReclutandoFase 2
Edades de 18 a 59 · Todos los sexos · Actualizado el 22 sept 2026 · NCT05554406A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib
- Dana-Farber Cancer Center, Boston
ReclutandoFase 1/2
Edades de 12 en adelante · Todos los sexos · Actualizado el 18 sept 2026 · NCT06284486A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
- UMass Memorial Medical Center - University Campus, Worcester
ReclutandoFase 3
6 Months – 21 Years · Todos los sexos · Actualizado el 17 sept 2026 · NCT04293562(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
- Dana-Farber Cancer Institute, Boston
ReclutandoFase 2
Edades de 18 en adelante · Todos los sexos · Actualizado el 15 sept 2026 · NCT04996875Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies
- Dana-Farber Cancer Institute, Boston
ReclutandoFase 1/2
Edades de 18 en adelante · Todos los sexos · Actualizado el 14 sept 2026 · NCT03471260Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
- Massachusetts General Hospital, Boston
ReclutandoFase 1/2
Edades de 12 en adelante · Todos los sexos · Actualizado el 3 sept 2026 · NCT04588922CIML NK Cells With Venetoclax for AML
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 28 ago 2026 · NCT06152809Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
ReclutandoFase 1
Edades de 18 a 90 · Todos los sexos · Actualizado el 26 ago 2026 · NCT07439211A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease
- Dana-Farber Cancer Institute, Boston
ReclutandoFase 1
Edades de 18 a 75 · Todos los sexos · Actualizado el 25 ago 2026 · NCT05886049Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML
- Dana-Farber Cancer Institute, Boston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 25 ago 2026 · NCT06533761The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Dana-Farber Cancer Institute, Boston
ReclutandoFase 1/2
Hasta los 22 · Todos los sexos · Actualizado el 25 ago 2026 · NCT04726241Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
- Dana-Farber Cancer Institute, Boston
ReclutandoFase 3
29 Days – 21 Years · Todos los sexos · Actualizado el 24 ago 2026 · NCT05183035Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
- Beth Israel Deaconess Medical Center, Boston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 20 ago 2026 · NCT06001788Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- University of Massachusetts, Worcester
ReclutandoFase 3
Edades de 18 en adelante · Todos los sexos · Actualizado el 20 ago 2026 · NCT07007312A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
- Brigham and Women's Hospital, Boston
ReclutandoFase 1Se aceptan voluntarios sanos
Edades de 18 a 75 · Todos los sexos · Actualizado el 28 jul 2026 · NCT07020533A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Tufts Medical Center, Boston
- Beth Israel Deaconess, Boston
- Dana Farber Cancer Institute, Boston
ReclutandoEstudio observacional
Todas las edades · Todos los sexos · Actualizado el 6 jul 2026 · NCT01351545Ivosidenib as Post-HSCT Maintenance for AML
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
ReclutandoFase 2
Edades de 18 a 75 · Todos los sexos · Actualizado el 18 jun 2026 · NCT06707493Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation
- Dana-Farber Cancer Institute, Boston
- Brigham and Women's Hospital, Boston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 17 jun 2026 · NCT06138587SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
- Dana Farber Cancer Institute, Boston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 17 jun 2026 · NCT03113643A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation
- Boston Children's Hospital, Boston
- Dana Farber Cancer Institute, Boston
ReclutandoFase 1
Edades de 12 en adelante · Todos los sexos · Actualizado el 17 jun 2026 · NCT04024761Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome
- Dana-Farber Cancer Institute, Boston
- Dana Farber Cancer Institute at St. Elizabeth's, Brighton
- Dana Farber Cancer Institute at Merrimack Valley, Methuen
- y 2 más
ReclutandoEstudio observacional
Edades de 18 en adelante · Todos los sexos · Actualizado el 7 may 2026 · NCT02269592Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
- Dana Farber Cancer Institute, Boston
ReclutandoFase 1
Edades de 13 en adelante · Todos los sexos · Actualizado el 5 may 2026 · NCT04771572Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML
- Beth Israel Deaconess Medical Center, Boston
ReclutandoFase 1
Todas las edades · Todos los sexos · Actualizado el 5 may 2026 · NCT07374029A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
- Dana-Farber Cancer Institute, Boston
ReclutandoFase 2/3
Edades de 18 en adelante · Todos los sexos · Actualizado el 30 abr 2026 · NCT04256317Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double and Triple Combination With Azacitidine and Venetoclax in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
- Massachusetts General Hospital, Boston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 8 abr 2026 · NCT06419634BCL2i CLAG-M in R/R Acute Myeloid Leukemia
- Dana-Farber Cancer Institute, Boston
ReclutandoFase 2
Edades de 18 a 80 · Todos los sexos · Actualizado el 1 abr 2026 · NCT06660368Revumenib in Combination With 7+3 + Midostaurin in AML
- Dana-Farber Cancer Institute, Boston
ReclutandoFase 1
Edades de 18 a 75 · Todos los sexos · Actualizado el 25 mar 2026 · NCT06313437A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Massachusetts General Hospital, Boston
ReclutandoFase 1/2
Edades de 12 en adelante · Todos los sexos · Actualizado el 24 mar 2026 · NCT04988555Ziftomenib Maintenance Post Allo-HCT
- Massachusetts General Hospital, Boston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 19 mar 2026 · NCT06440135A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
- Dana-Farber Cancer Institute, Boston
ReclutandoFase 2
Edades de 18 a 66 · Todos los sexos · Actualizado el 17 mar 2026 · NCT06859424A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
- Dana Farber Cancer Institute, Boston
ReclutandoFase 1
Edades de 12 en adelante · Todos los sexos · Actualizado el 16 mar 2026 · NCT06994676A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- Massachusetts General Hospital, Boston
- UMass Chan Medical School, Worcester
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 13 mar 2026 · NCT05735184CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
- DFCI/BWH Brigham and Women's Hospital, Boston
ReclutandoFase 2Se aceptan voluntarios sanos
Edades de 18 a 75 · Todos los sexos · Actualizado el 10 mar 2026 · NCT06059391A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)
- DFCI, Boston
ReclutandoFase 1
Edades de 18 en adelante · Todos los sexos · Actualizado el 9 feb 2026 · NCT06950034De ClinicalTrials.gov, datos obtenidos el 1 oct 2026. Cada estudio establece sus propios criterios de elegibilidad; el equipo del estudio decide quién puede participar.